Ocugen licenses OCU400 gene therapy to Roots Pharma for MENA
Ocugen has completed a licensing agreement with Kuwait-based Roots Pharmaceutical, granting the MENA-focused company exclusive rights to commercialise OCU400, its modifier gene therapy for retinitis pigmentosa (RP), across the Middle East and North Africa. The deal was announced on 14 October 2026 and includes a related supply agreement under which Ocugen will manufacture commercial product.
The financial terms include an upfront licence fee and early development payments totalling up to $4 million, potential sales milestone payments of up to $255 million, and royalties set at 22% of OCU400 net sales generated by Roots Pharmaceutical. The arrangement follows a structure common in regional out-licensing deals, where a US-listed developer retains manufacturing and global regulatory control while a local partner handles market access and distribution.
The deal
Ocugen described RP prevalence in the MENA region as ten to twenty times higher than in the United States or European Union, citing consanguinity rates and population genetics as contributing factors. The company says that elevated disease burden makes the region a strategically significant commercial territory for a potential one-time gene therapy. Roots Pharmaceutical, which was founded in Kuwait in 2006 and holds ISO 9001:2015 certification, operates across GCC countries and key North African markets, with a portfolio spanning neurology, haematology, oncology and rare diseases.
Shankar Musunuri, chairman, chief executive and co-founder of Ocugen, said the agreement represents "another important step in our strategy to build strong regional partnerships and expand global access to our potentially transformational gene therapies." Roots chief executive Islam Zayed added that the company intends to build out a "diagnosis-to-treatment pathway" suited to the infrastructure requirements of gene therapy delivery across MENA markets, an important practical consideration given that one-time gene therapies require specialist clinical settings and cold-chain logistics.
Regulatory and competitive context
OCU400 is being evaluated in Ocugen's Phase 3 liMeliGhT clinical trial, with topline data expected in the first quarter of 2027. If that readout is positive, Ocugen has said it plans to file a Biologics License Application with the US FDA and a Marketing Authorisation Application with the European Medicines Agency. The MENA licence agreement is structured to follow those submissions, with commercial milestone payments contingent on sales performance.
The broader inherited retinal disease market has attracted significant investment in recent years. Spark Therapeutics' Luxturna, which targets RPE65-mediated RP, was the first approved gene therapy for an inherited retinal dystrophy, but its single-gene mechanism leaves the large majority of RP patients, who carry mutations across more than 100 different genes, without a targeted option. Ocugen's modifier gene therapy approach is designed to act in a gene-agnostic manner, modulating disease biology across multiple gene networks rather than correcting a single mutation. If the Phase 3 data support that mechanism, the addressable RP population could be materially larger than single-gene approaches allow.
Several other developers, including groups with university-spinout origins, are pursuing gene-agnostic or broad-spectrum strategies for inherited retinal diseases, and the field remains competitive at the preclinical and early clinical stages. The strength of OCU400's Phase 3 readout in early 2027 will be closely watched as a potential indicator of how durable the modifier platform approach is relative to more conventional gene-correction therapies. For Roots Pharmaceutical, the agreement also opens a path to explore further collaboration across Ocugen's ophthalmology pipeline, which includes programmes for Stargardt disease and geographic atrophy.